These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25105925)

  • 1. 1,3,5-Triazine-based analogues of purine: from isosteres to privileged scaffolds in medicinal chemistry.
    Lim FP; Dolzhenko AV
    Eur J Med Chem; 2014 Oct; 85():371-90. PubMed ID: 25105925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fused Heterocyclic Systems with an s-Triazine Ring. 34. Development of a Practical Approach for the Synthesis of 5-Aza-isoguanines.
    Junaid A; Lim FPL; Zhou YP; Chui WK; Dolzhenko AV
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolo[4,3-e][1,2,4]triazines: purine analogues with electronic absorption in the visible region.
    Mojzych M; Rykowski A; Wierzchowski J
    Molecules; 2005 Oct; 10(10):1298-306. PubMed ID: 18007523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets.
    Legraverend M; Grierson DS
    Bioorg Med Chem; 2006 Jun; 14(12):3987-4006. PubMed ID: 16503144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development, Potential Anticancer Activity and the Receptor Profile of Different Functionalized 1,3,5-Triazine Derivatives.
    Sarhan MO; Motaleb MA; Ibrahim IT; Anwar MM; Zaghary WA
    Mini Rev Med Chem; 2018; 18(15):1302-1320. PubMed ID: 28971773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry.
    Song Y; Zhan P; Zhang Q; Liu X
    Curr Pharm Des; 2013; 19(8):1528-48. PubMed ID: 23131184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle.
    Ott GR; Favor DA
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4238-4246. PubMed ID: 28801135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Privileged s-triazines: structure and pharmacological applications.
    Shah DR; Modh RP; Chikhalia KH
    Future Med Chem; 2014 Mar; 6(4):463-77. PubMed ID: 24635525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
    Cancilla MT; He MM; Viswanathan N; Simmons RL; Taylor M; Fung AD; Cao K; Erlanson DA
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3978-81. PubMed ID: 18579375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase.
    Biagi G; Costantini A; Costantino L; Giorgi I; Livi O; Pecorari P; Rinaldi M; Scartoni V
    J Med Chem; 1996 Jun; 39(13):2529-35. PubMed ID: 8691450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of aziridine- and β-lactam-based hybrids as both bioactive substances and synthetic intermediates in medicinal chemistry.
    Vandekerckhove S; D'hooghe M
    Bioorg Med Chem; 2013 Jul; 21(13):3643-7. PubMed ID: 23684232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolo[4,5-d]pyrimidines as a privileged scaffold in drug discovery.
    Kuppast B; Fahmy H
    Eur J Med Chem; 2016 May; 113():198-213. PubMed ID: 26942627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
    Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
    Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,2,4-triazine analogs as novel class of therapeutic agents.
    Kumar R; Sirohi TS; Singh H; Yadav R; Roy RK; Chaudhary A; Pandeya SN
    Mini Rev Med Chem; 2014 Feb; 14(2):168-207. PubMed ID: 24479860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel solution-phase synthesis of a 2,6,8,9-tetrasubstituted purine library via a sulfur intermediate.
    Liu J; Dang Q; Wei Z; Zhang H; Bai X
    J Comb Chem; 2005; 7(4):627-36. PubMed ID: 16004508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors of thymidine phosphorylase.
    Sun L; Bera H; Chui WK
    Eur J Med Chem; 2013 Jul; 65():1-11. PubMed ID: 23688695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Developments and Future Perspectives of Purine Derivatives as a Promising Scaffold in Drug Discovery.
    Rana N; Grover P; Singh H
    Curr Top Med Chem; 2024; 24(6):541-579. PubMed ID: 38288806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of calf spleen purine nucleoside phosphorylase complexed to a novel purine analogue.
    Pereira HM; Berdini V; Cleasby A; Garratt RC
    FEBS Lett; 2007 Oct; 581(26):5082-6. PubMed ID: 17927987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.